Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics. Issue 24 (22nd July 2021)

• Record Type: Journal Article
• Authors: Rodriguez-Gil, Jorge L; Baxter, Laura L; Watkins-Chow, Dawn E; Johnson, Nicholas L; Davidson, Cristin D; Carlson, Steven R; Incao, Arturo A; Wallom, Kerri L; Farhat, Nicole Y; Platt, Frances M; Dale, Ryan K; Porter, Forbes D; Pavan, William J
• Is Part Of: Human molecular genetics. Volume 30:Issue 24(2021)
• Page Start: 2456
• Page End: 2468
• Publication Date: 2021-07-22
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddab194
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: The rare, fatal neurodegenerative disorder Niemann-Pick disease type C1 (NPC1) arises from lysosomal accumulation of unesterified cholesterol and glycosphingolipids. These subcellular pathologies lead to phenotypes of hepatosplenomegaly, neurological degeneration and premature death. The timing and severity of NPC1 clinical presentation is extremely heterogeneous. This study analyzed RNA-Seq data from 42 NPC1 patient-derived, primary fibroblast cell lines to determine transcriptional changes induced by treatment with 2-hydroxypropyl-β-cyclodextrin (HPβCD), a compound currently under investigation in clinical trials. A total of 485 HPβCD-responsive genes were identified. Pathway enrichment analysis of these genes showed significant involvement in cholesterol and lipid biosynthesis. Furthermore, immunohistochemistry of the cerebellum as well as measurements of plasma from Npc1 m1N null mice treated with HPβCD and adeno-associated virus gene therapy suggests that one of the identified genes, GPNMB, may serve as a useful biomarker of treatment response in NPC1 disease. Overall, this large NPC1 patient-derived dataset provides a comprehensive foundation for understanding the genomic response to HPβCD treatment.